PXD009380

PXD009380 is an original dataset announced via ProteomeXchange.

Title	Kinome profiling of diffuse large B-cell lymphoma cells in response to dasatinib
Description	Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, with at least one-third of its patients not responding to the current chemotherapy regimen, R-CHOP. By gene expression profiling, patients with DLBCL can be categorized into two clinically relevant subtypes: activated B-cell (ABC) DLBCL and germinal center B-cell (GCB). Patients with ABC DLBCL have a worse prognosis, and are defined by chronic, overactive signaling through the B-cell receptor and NF-κB pathways. We examined the effects of the Src family kinase (SFK) inhibitor dasatinib in a panel of ABC and GCB DLBCL cell lines, and found that the ABC DLBCL cell lines are much more sensitive to dasatinib than the GCB DLBCL cell lines. However, using multiplexed inhibitor bead coupled to mass spectrometry (MIB/MS) kinome profiling competition and western blot analysis, both subtypes display inhibition of the SFKs in response to dasatinib after both short- and long-term treatment. MIB/MS analyses revealed several cell cycle kinases, including CDK4, CDK6, and the Aurora kinases, are inhibited by dasatinib treatment in the ABC DLBCL subtype, but not in the GCB DLBCL subtype. The present findings have important implications for the clinical use of dasatinib for the treatment of ABC DLBCL, either alone or in combination with other agents.
HostingRepository	PRIDE
AnnounceDate	2018-12-14
AnnouncementXML	Submission_2018-12-14_02:24:48.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Laura Herring
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	No PTMs are included in the dataset
Instrument	Q Exactive

Revision	Datetime	Status	ChangeLog Entry
0	2018-04-03 08:15:39	ID requested
⏵ 1	2018-12-14 02:24:50	announced

Cann ML, Herring LE, Haar LL, Gilbert TSK, Goldfarb D, Richards KL, Graves LM, Lawrence DS, Dasatinib Is Preferentially Active in the Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma. J Proteome Res, 18(1):522-534(2019) [pubmed]

curator keyword: Biomedical

submitter keyword: kinome, lymphoma, cancer, dasatinib, LC-MS

Laura E. Herring
contact affiliation	UNC Proteomics Core Facility, Department of Pharmacology, University of North Carolina at Chapel Hill
contact email	laura_herring@med.unc.edu
lab head
Laura Herring
contact affiliation	UNC-Chapel Hill
contact email	laura_herring@med.unc.edu
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/12/PXD009380

PRIDE project URI

• PRIDE
  1. PXD009380
     1. Label: PRIDE project
     2. Name: Kinome profiling of diffuse large B-cell lymphoma cells in response to dasatinib